Zymeworks (ZYME) Asset Utilization Ratio (2022 - 2026)
Zymeworks (ZYME) posted Asset Utilization Ratio of 0.2 for Q1 2026, down 30.84% sequentially from 0.28 in Q4 2025, and down 6.24% YoY from 0.21 in Q1 2025.
Zymeworks (ZYME) Asset Utilization Ratio (2022 - 2026) Analysis & Trends
Zymeworks has reported Asset Utilization Ratio for 5 years, with the latest figure at 0.2 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 6.24% year-over-year to 0.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.2 (down 6.24% YoY) and the FY2025 annual result came in at 0.26, up 79.07% from the prior year.
- Asset Utilization Ratio slipped to 0.2 in Q1 2026 per ZYME's latest filing, from 0.28 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.71 in Q4 2022 and troughed at 0.09 in Q1 2024.
- A 5-year average of 0.32 and a median of 0.25 in 2025 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2024 and 2025: Asset Utilization Ratio sank 84.93% in 2024, then jumped 169.11% in 2025.
- Over 5 years, Asset Utilization Ratio stood at 0.71 in 2022, then plunged by 81.07% to 0.13 in 2023, then climbed by 20.14% to 0.16 in 2024, then surged by 77.42% to 0.28 in 2025, then slumped by 30.84% to 0.2 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.2, 0.28, and 0.33 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | 0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.08 |
| Mar 31, 2026 | 0.20 |
| Dec 31, 2025 | 0.28 |
| Sep 30, 2025 | 0.33 |
| Jun 30, 2025 | 0.29 |
| Mar 31, 2025 | 0.21 |
| Dec 31, 2024 | 0.16 |
| Sep 30, 2024 | 0.12 |
| Jun 30, 2024 | 0.12 |
| Mar 31, 2024 | 0.09 |
| Dec 31, 2023 | 0.13 |
| Sep 30, 2023 | 0.66 |
| Jun 30, 2023 | 0.62 |
| Mar 31, 2023 | 0.59 |
| Dec 31, 2022 | 0.71 |